Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase II FLOT regimen in advanced gastric or esophagogastric junction cancer
2005-004135-22Phase 2Completed
- Sponsor
- Krankenhaus Nordwest
- Start
- Nov 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, fluorouracil, folinic acid and oxaliplatin in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Krankenhaus Nordwest. Primary endpoint: Response rate. Started Nov 2005; status: completed.
02
Drugs
docetaxelfluorouracilfolinic acidoxaliplatin
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2005-004135-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004135-22.